Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 405-040-6 | CAS number: 63500-71-0 CIS/TRANS-TIMO; FLOROL; FLOROSA
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeated dose toxicity -
NOAEL (male/female) = 125 mg/kg bw/d (gavage, OECD 407, GLP)
NOAEL (male/female) = 1000 mg/kg bw/d (dermal, OECD 411, GLP)
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
Oral administration
Pyranol was administered orally (gavage) to rats in a repeated dose (28 day) toxicity study according to GLP and equivalent to OECD TG 407 (Toxicol Laboratories 1989, FCH/2/88). Three groups of 10 male and 10 female Crl:CD(SD) BR strain (VAF plus) rats received a suspension of Pyranol in 1% aqueous hydroxypropylmethylcellulose by gavage at dose levels of 25, 125 or 625 mg/kg bw/day whilst the fourth group received 1% aqueous hydroxypropylmethylcellulose alone and acted as control. All animals were dosed once daily for 4 weeks until the day before necropsy.
No deaths occurred during the whole study period. Administration of Pyranol by gavage at a dose level of 625 mg/kg bw/day was associated with minor changes only. These included salivation, changes in coat condition, marginal reductions in red blood cell values (dubious biological significance), moderate increases in plasma triglycerides, the presence of ketones in the urine (males only) and slightly raised liver weight and adrenal weight (females only). The increases in plasma triglycerides, associated with increased liver weight, are considered to be genuine effects. In the absence of any microscopic evidence of hepatotoxicity, these probably reflect physiological adaptation to the metabolism of a xenobiotic. The presence of ketones in the urine of males is significant since ketones are not normally found in rat urine. Possibly, this response arises from breakdown products of the test article. Bodyweight gain and food intake were unaffected by treatment.The remaining changes are considered to be of doubtful significance.
In conclusion the NOAEL of Pyranol for repeated dose toxicity study in SD-rats was defined as 125 mg/kg bw/d.
Dermal administration
The described data above indicate that Pyranol is of relatively low toxicity via the oral route. The primary route of exposure when in use is via skin contact as Pyranolis a fragrance material and only present in dermal consumer products (i.e. cosmetics, laundry care products). Exposure of humans via the oral route can therefore practically be excluded and is irrelevant compared to the primary route of exposure which is dermal. Besides, an in vitro study on dermal penetration of 14C-Pyranol through rat skin (according to OECD 428 and GLP, see also IUCLID chapter 7.1.2) showed significant dermal absorption. In order to address the endpoint of sub-chronic toxicity of Pyranol a 90-day repeated dose study in rats, oral route (according to OECD 411) was performed (BASF SE 2014, 82R0639/09R137). Pyranol was administered 5 days per week to male and female Wistar rats dermally at dose levels of 0 (test group 0), 100 (test group 1), 300 (test group 2) and 1000 (test group 3) mg/kg bw/day over a period of 90 days. Each test group consisted of 10 animals per sex.
Some male and female animals showed slight erythema, erosion and scales. These finding are attributed to the irritating properties of the test substance. No other test substance-related effects concerning clinical signs, body weight food consumption, water consumption, haematology, clinical chemistry, urinalysis, neurobehaviour, organ weights and histopathology were observed. Therefore, the NOEAL for repeated dose toxicity of this study was set to 1000 mg/kg bw/day.
Inhalation
There are no data available.
Conclusion
In a dermal 90 day repeated dose toxicity study (BASF SE, 2015), apart from slight erythema, erosion and scales in some animals no other thest substance related effects were observed. Therefore, the NOAEL was set to 1000 mg/kg bw/day.
In an oral 28 day repeated dose study (Toxicol Laboratories 1989, FCH/2/88), there was no substance-specific organotoxicity detectable after 28 day repeated oral administration of Pyranol to rats. As treatment-related findings in the study, salivation, changes in coat condition, minor changes in haematological and clinical chemistry parameters, increased liver weight (without histological correlation) as well as ketones in the urine (males only) were observed at 625 mg/kg bw/day.
In conclusion, the NOAEL for repeated dose toxicity has been set at 125 mg/kg bw/day.
Justification for classification or non-classification
Based on the available data, Pyranol (Tetrahydro-4-methyl-2-(2-methylpropyl)-2H-pyran-4-ol) is not subjected to classification and labelling for repeated dose or specific target organ toxicity according to Directive 67/548/EEC and Regulation 1272/2008/EC.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.